Filing Flows › Comparisons › JANX vs RCUS
Janux Therapeutics vs Arcus Biosciences: JANX and RCUS compared
Janux Therapeutics is the larger company: $9.3M of revenue in its latest quarter (Q3 2026) against $9.0M for Arcus Biosciences (Q3 2026). Janux Therapeutics is growing faster (-7% against -65% a year earlier).
Where the money goes: JANX and RCUS
Janux Therapeutics (JANX) · Q3 2026
Janux Therapeutics, Q3 2026: revenue $9.3M (-7% year over year), operating margin -336.5%, net loss $21.6M, operating cash flow −$25.2M. The chart follows the revenue to costs, profit and cash.
Arcus Biosciences (RCUS) · Q3 2026
Arcus Biosciences, Q3 2026: revenue $9.0M (-65% year over year), net loss $128M, operating cash flow −$88.0M. The chart follows the revenue to costs, profit and cash.
| Janux Therapeutics (JANX) | Arcus Biosciences (RCUS) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $9.3M | $9.0M |
| Revenue growth, Y/Y | -7% | -65% |
| Operating margin | -336.5% | n/m |
| Net earnings | −$21.6M | −$128M |
| Net margin | -232.2% | — |
| Operating cash flow | −$25.2M | −$88.0M |
| Market value | $1.2B | — |
| Analysts’ mean target | $32.53 | — |
Where the revenue comes from
Arcus Biosciences
- License and development services: $8.0M (89%)
- Other collaboration: $1.0M (11%)
Questions
Which is bigger, Janux Therapeutics or Arcus Biosciences?
Janux Therapeutics is the larger company: $9.3M of revenue in its latest quarter (Q3 2026) against $9.0M for Arcus Biosciences (Q3 2026).
Is Janux Therapeutics or Arcus Biosciences growing faster?
Janux Therapeutics is growing faster (-7% against -65% a year earlier).
More: Janux Therapeutics earnings · how Janux Therapeutics makes money · Arcus Biosciences earnings · how Arcus Biosciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.